Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: various stages of PDAC
I · Intervention 중재 / 시술
the standard-of-care therapies FOLFIRINOX, gemcitabine plus paclitaxel, or the antibody-drug conjugate enfortumab vedotin
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Targeting Nectin-4 with the antibody-drug conjugate enfortumab vedotin inhibited tumor growth in multiple patient-derived PDAC organoids. Collectively, our data underscore Nectin-4 as a potential novel therapeutic target and provide the rationale to test this agent in patients with PDAC.
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and current therapies show limited efficacy.
APA
Heiduk M, Beer C, et al. (2026). Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.. JCI insight, 11(2). https://doi.org/10.1172/jci.insight.194290
MLA
Heiduk M, et al.. "Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.." JCI insight, vol. 11, no. 2, 2026.
PMID
41364531 ↗
Abstract 한글 요약
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and current therapies show limited efficacy. Ligands and receptors of the TIGIT axis were analyzed using multicolor flow cytometry of tumor and blood samples, IHC from primary tumors, and single-cell RNA-Seq from primary tumors and liver metastasis from patients with various stages of PDAC. The effect of soluble and plate-bound Nectin-4 on T cell function was tested in vitro. Furthermore, patient-derived PDAC organoids were treated with the standard-of-care therapies FOLFIRINOX, gemcitabine plus paclitaxel, or the antibody-drug conjugate enfortumab vedotin. TIGIT expression was increased on tumor-infiltrating conventional T cells and Tregs compared with T cells from matched blood. Nectin-4 but not CD155 expression was associated with poor outcome. Nectin-4 was exclusively expressed by tumor cells and correlated with low immune infiltration. Notably, Nectin-4 inhibited T cell effector cytokine production in vitro. Targeting Nectin-4 with the antibody-drug conjugate enfortumab vedotin inhibited tumor growth in multiple patient-derived PDAC organoids. Collectively, our data underscore Nectin-4 as a potential novel therapeutic target and provide the rationale to test this agent in patients with PDAC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Pancreatic Neoplasms
- Carcinoma
- Pancreatic Ductal
- Cell Adhesion Molecules
- T-Lymphocytes
- Receptors
- Immunologic
- Deoxycytidine
- Gemcitabine
- Female
- Antineoplastic Combined Chemotherapy Protocols
- Animals
- Cell Line
- Tumor
- Paclitaxel
- Lymphocytes
- Tumor-Infiltrating
- Mice
- Leucovorin
- Male
- Oxaliplatin
- Nectins
- Cancer
… 외 3개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.